- Home
- ATYR vs DXR Comparison
ATYR vs DXR Comparison
Compare ATYR & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATYR | DXR |
|---|---|---|
| Founded | 2005 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.2M | 59.0M |
| IPO Year | 2015 | 1995 |
Fundamental Metrics
Financial Performance| Metric | ATYR | DXR |
|---|---|---|
| Price | $0.54 | $9.80 |
| Analyst Decision | Hold | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $3.67 | N/A |
| AVG Volume (30 Days) | ★ 583.2K | 2.2K |
| Earning Date | 05-01-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.98 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $190,000.00 | ★ $1,446,345.00 |
| Revenue This Year | N/A | $44,935.22 |
| Revenue Next Year | N/A | $74.79 |
| P/E Ratio | ★ N/A | $33.83 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.40 | $8.56 |
| 52 Week High | $6.50 | $14.76 |
Technical Indicators
Market Signals| Indicator | ATYR | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 53.31 | 38.46 |
| Support Level | $0.46 | $9.64 |
| Resistance Level | $0.60 | $11.16 |
| Average True Range (ATR) | 0.04 | 0.25 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 49.73 | 8.30 |
Price Performance
Historical ComparisonAbout ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.